Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Phenindione→

Phenindione Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
83-12-5
Molecular formula
C15H10O2
Molecular weight
222.24 g/mol
Drug class
Indandione oral anticoagulantvitamin K antagonist
Mechanism of action
Interferes with hepatic synthesis of functional vitamin K-dependent coagulation factors II, VII, IX and X, reducing the blood’s capacity to form thrombin and fibrin clots.
Indications / reported uses
  • Prevention and treatment of venous thrombosis and pulmonary embolism.
  • Prevention of systemic embolisation in selected patients with atrial fibrillation and rheumatic heart disease, and after insertion of prosthetic heart valves, under the product label and INR monitoring.

Sources: https://www.medicines.org.uk/emc/product/5677/smpc · https://www.medicines.org.uk/emc/product/5678/smpc

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Phenindione Environmental Risk Assessment (ERA) (the Phenindione ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.